MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/30/2026

1. META
2. MSFT
3. FTNT
4. TENB
5. CVNA
6. ARM
7. SBUX
8. QCOM
9. CLH
10. ICE

Go back to MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients
Medicinova, Inc. (NASDAQ: MNOV) Delayed: 1.29 --0 (-0%)
Previous Close $1.29    52 Week High $10.16 
Open $1.29    52 Week Low $2.91 
Day High $1.29    P/E N/A 
Day Low $1.29    EPS $-0.41 
Volume 2